Verition Fund Management’s Medifast MED Stock Holding History

Verition Fund Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,000	Closed	-$1.1M	–	873
2019 Q4	$1.1M	Buy	+10,000	New	+$968K	0.02%	424

Other funds holding MED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $403M AUM 43.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Verition Fund Management's MED Position: Q1 2026 in Review

Verition Fund Management sold out of Medifast (MED) in Q1 2026, closing a stake of 24,842 shares — an estimated $265K sold.

Verition Fund Management first reported a position in MED in Q2 2018 and held it in 8 quarters. The position peaked at $1.7M in Q4 2019. 111 funds tracked by Wall St. Rank hold MED as of Q1 2026.

Verition Fund Management reported no remaining Medifast position as of Q1 2026 after selling out during the quarter.
Verition Fund Management sold 24,842 Medifast shares in Q1 2026, an estimated $265K.
Verition Fund Management first reported a position in Medifast in Q2 2018 and held it in 8 quarters.
Verition Fund Management's Medifast position peaked at $1.7M in Q4 2019.
111 funds tracked by Wall St. Rank held Medifast as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.